文献速递新生儿儿童神经与发育行为儿童消化与营养

极早产儿益生菌接收与神经发育结局的队列研究

Probiotic Receipt and Neurodevelopmental Outcomes of Infants <29 Weeks' Gestation: A Cohort Study.
PubMed 文献 · J Pediatr · 2025-08-20

该研究基于加拿大21个新生儿病房的国家代表性回顾性队列,纳入2014至2020年出生、胎龄<29周且存活至18–30月龄随访的儿童,比较接受与未接受益生菌者的显著神经发育损害。逻辑回归显示两组等效,倾向评分匹配分析提示益生菌可能更优,且未观察到生长方面的危害。

要点

  • 益生菌组与无益生菌组的显著神经发育损害在逻辑回归中达到等效。
  • 倾向评分匹配分析提示益生菌可能优于无益生菌,但结果与主分析不一致。
  • 多数次要结局包括生长结局两组相似,未观察到益生菌相关危害。

核心结论

  • 在<29周存活早产儿中,益生菌与神经发育和生长方面的危害无关,且可能对神经发育和生长有潜在优势。

研究设计与样本

  • 国家代表性、多中心、回顾性队列研究,比较接受与未接受益生菌的儿童。

主要发现

  • 益生菌组2749例(中位胎龄26周、出生体重920克),无益生菌组2442例(中位胎龄26周、出生体重890克),基线特征相似。
  • 逻辑回归分析显示益生菌与无益生菌在显著神经发育损害上等效(校正RD -0.23%,95%CI:2.61%,2.15%)。
  • 倾向评分匹配分析(1474对儿童)显示益生菌非等效且可能更优(校正RD -4.01%,95%CI:6.92%,-1.01%)。
  • 多数次要结局包括生长结局两组相似。

关键数值与推荐

  • 显著神经发育损害定义为Bayley婴幼儿发育量表第三版认知、语言或运动评分<70,或脑性瘫痪伴粗大运动功能分类系统III–V级,或需助听器/人工耳蜗,或双侧视力损害。
  • 等效分析采用4%界值,通过逻辑回归和倾向评分匹配计算校正风险差及置信区间。

临床怎么用

  • 对于<29周存活早产儿,益生菌未显示神经发育和生长方面的危害,可结合病房常规和个体情况考虑使用。
  • 应向家长说明证据存在分析方式间的不一致,倾向评分匹配结果提示潜在获益但需谨慎解读。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine neurodevelopment and growth following probiotic receipt in neonatal intensive care units. STUDY DESIGN: A national, population-representative, multicenter, retrospective cohort study was conducted on children born at <29 weeks' gestation between January 1, 2014, and December 31, 2020, from 21 neonatal units in Canada who survived and then underwent follow-up between ages 18 and 30 months. Children who received vs did not receive probiotics were compared for the primary outcome of significant neurodevelopmental impairment, defined as any of the following: Bayley Scales of Infant and Toddler Development-III cognitive, language, or motor score <70; cerebral palsy with Gross Motor Function Classification System III-V; hearing aid or cochlear implant; or bilateral visual impairment. Equivalence analyses utilizing a 4% margin for outcomes between groups were conducted using logistic regression and propensity score-matched analyses to calculate adjusted risk difference (RD) and CIs. RESULTS: A total of 2749 children in the probiotics group (median gestation 26 weeks and birth weight 920 grams) and 2442 in the no probiotics group (median gestation 26 weeks and birth weight 890 grams) were evaluated. Baseline characteristics were similar between groups. For the outcome of significant neurodevelopmental impairment, logistic regression analyses indicated that probiotics were equivalent to no probiotics (adjusted RD -0.23%, 95% CI: 2.61%, 2.15%), whereas propensity score-matched analyses (1474 pairs of children) indicated probiotics were nonequivalent and potentially superior (adjusted RD -4.01%, 95% CI: 6.92%, -1.01%). Results of the majority of secondary outcomes were similar, including growth outcomes. CONCLUSIONS: Probiotics were not associated with harm in neurodevelopment and growth of surviving preterm neonates and may be potentially superior to no probiotics for neurodevelopment and growth among surviving preterm neonates <29 weeks' gestation.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Shah PS, Bando N, Lee S, et al. Probiotic Receipt and Neurodevelopmental Outcomes of Infants <29 Weeks' Gestation: A Cohort Study. J Pediatr. 2025. PMID: 40846205. doi:10.1016/j.jpeds.2025.114783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。